Form 6-K GENETIC TECHNOLOGIES For: Nov 25

�

FORM�6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

�

dated November�25, 2014

�

Commission File Number 0-51504

�

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

�

N/A

(Translation of Registrant�s Name)

�

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form�20-F or Form�40-F.

�

Form�20-F��x����������Form�40-F��o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(1):��o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(7):��o

�

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule�12g3-2(b)�under the Securities Exchange Act of 1934.

�

Yes��o������������������������������������������������������������������� No��x

�

If �Yes� is marked, indicate below the file number assigned to the registrant in connection with Rule�12g3-2(b):� Not applicable.

�

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

�

Date:� November�25, 2014

�

�

�

2

�

EXHIBIT�INDEX

�

�

3

Exhibit�99.1

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

Exhibit�99.2

�

ASX ANNOUNCEMENT

25 November�2014

�

Intention of Board to offer Share Purchase Plan (�SPP�)

�

Melbourne, Australia, 25 November�2014:� Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, �Company�) today announced that where all of the resolutions regarding the capital raising are passed at today�s AGM, the Board intends to offer existing shareholders the opportunity to acquire further Company shares at the same pricing as calculated under the Convertible Note.� The pricing for both the Convertible Note and any offer under the SPP will be determined and announced to the market at the same time.

�

FOR FURTHER INFORMATION PLEASE CONTACT

�

�

About Genetic Technologies Limited

�

Genetic Technologies was an early pioneer in recognizing important new applications for �non-coding� DNA (Deoxyribonucleic Acid).� The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species.� Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio.� Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act.� The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�

Genetic Technologies Limited � Website: www.gtglabs.com � Email: [email protected] �ABN 17 009 212 328

Registered Office � 60-66 Hanover Street Fitzroy Victoria 3065 Australia � Postal Address P.O.�Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 � Fax +61 3 8412 7040

�

Exhibit�99.3

�

ASX ANNOUNCEMENT

25 November�2014

�

Key Managerial Appointments following the Resignation of CEO

�

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, �Company�) wishes to announce key managerial appointments following the resignation of Ms.�Alison Mew as Chief Executive Officer. Effective 31 December�2014, Ms.�Alison Mew has decided to step down from her position of CEO, for personal, health-related reasons.

�

The Company�s Chairman, Dr.�Mal Brandon said �The Board is extremely disappointed to have to announce Ms.�Mew�s resignation and though regretful, the Board fully understands and supports her decision to step down. The Board wishes to express its thanks and gratitude to Ms.�Mew for her dedication, commitment and contribution during her time with the Company. Ms.�Mew has played a key role in the establishment of the Company�s U.S. operations along with securing the Australian Laboratory�s U.S compliance, and most recently the successful launch of the 2nd generation breast cancer risk assessment test, BREVAGenplus�. The Board, Management and all the Staff wish Ms.�Mew the very best for her future�.

�

The Board also wishes to announce that, following the resignation of Ms.�Alison Mew, Mr.�Eutillio Buccilli, the Company�s current Chief Financial Officer, has been appointed to the position of Chief Operating Officer and Chief Financial Officer and that Mr.�Mark Ostrowski, currently Senior VP Sales and Marketing, Phenogen Sciences Inc., based in the U.S., will assume the role of President, Phenogen Sciences Inc. Both new appointments become effective immediately.

�

The Company will immediately commence an international search for a new CEO.

�

Mr.�Eutillio Buccilli

�

Mr.�Buccilli joined the Company in June�2014, after more than 35 years of senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with blue chip corporations such as General Electric (�GE�), Computer Science Corporation, Coles Myer and Challenger Limited. Whilst at GE, Mr.�Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut.

�

Mr.�Buccilli possesses significant level of expertise including financial, corporate governance and commercial experience, with a strong emphasis on financial and corporate management. Since his appointment, Mr.�Buccilli has been instrumental in driving change and has played a pivotal role in implementing the restructure and realignment of group activities program that was approved by the Board following the corporate wide operational review. Mr Buccilli will be assisted by the Board and external advisors, in specific technical and commercial aspects of the healthcare business, as required.

�

Mr.�Mark Ostrowski

�

Mr.�Ostrowski joined the Company in September�2012, and was appointed to the position of Senior VP Sales and Marketing. Mr Ostrowski possesses over 20 years of sales and marketing experience in molecular diagnostics having served in senior managerial positions at companies focused on women�s health and oncology, including as Director of Sales Operations at Myriad Genetics (NASDAQ: MYGN) and Director� of Managed Care Services at DIANON Systems (NASDAQ: DIAN).

�

Prior to joining the Company, Mr.�Ostrowski�s career spanned both early stage and established biomedical companies. During his tenure at Myriad, he had comprehensive exposure to all aspects of sales and

�

�

marketing, managing a sales force of over 200 representatives, demonstrating average annual revenue growth of over 50%, and generating new strategic divisions and best practice policies.

�

Mr Ostrowski�s in-depth knowledge of the diagnostics space and sales managerial leadership has played a key role in facilitating acceptance and growth for the Company�s flagship lead breast cancer risk test, BREVAGenTM, and subsequently spearheaded the successful launch of the 2nd generation BREVAGenplus.

�

Dr.�Mal Brandon said �The Board is extremely pleased with the appointment of Mr.�Eutillio Buccilli and Mr.�Mark Ostrowski to their new roles. The Board is confident that both are well placed to lead the Company through its next stages of development in both Australia and the U.S., and that the Company will continue to meet the milestones and achieve success as it continues to build its molecular testing diagnostics business in the U.S�.

�

FOR FURTHER INFORMATION PLEASE CONTACT

�

�

About Genetic Technologies Limited

�

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting.� The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE).� Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets.� Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women�s health.� Phenogen�s lead product, BREVAGen�, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

�

For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act� The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�

Genetic Technologies Limited � Website: www.gtglabs.com � Email: [email protected] �ABN 17 009 212 328

Registered Office � 60-66 Hanover Street Fitzroy Victoria 3065 Australia � Postal Address P.O.�Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 � Fax +61 3 8412 7040

�

Exhibit�99.4

�

ASX ANNOUNCEMENT

25 November, 2014

�

Results from 2014 Annual General Meeting

�

Melbourne, Australia; 25 November�2014: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, �Company�) advises that the 2014 Annual General Meeting of shareholders was held at 10.30 am today (Melbourne time).

�

All nine (9)�resolutions that were put before the shareholders were passed on a show of hands.� Details of the proxy votes received by the Company in respect of all nine resolutions is contained in Table 1 to this announcement on the attached page.

�

FOR FURTHER INFORMATION PLEASE CONTACT

�

Alison Mew����������������������������������������������������������������������������������������������������������������������������������������������������������������������������� Candice Knoll (USA)

Chief Executive Officer��������������������������������������������������������������� Blueprint Life Science Group

�

Genetic Technologies Limited������������������������������������������������������������������������������� +1 (415) 375 3340, Ext. 105

Phone: +61 3 8412 7000

�

About Genetic Technologies Limited

�

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting.� The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE).� Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets.� Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women�s health.� Phenogen�s lead product, BREVAGen�, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

�

For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�

�

Table 1 - Proxy results for 2014 Annual General Meeting

�

�

Note:����������������� The Company currently has a total of 751,034,632 ordinary shares on issue and 2,793 registered shareholders.

�

Genetic Technologies Limited� Website: www.gtglabs.com � Email: [email protected]���� ABN 17 009 212 328

Registered Office� 60-66 Hanover Street Fitzroy Victoria 3065 Australia � Postal Address P.O.�Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 � Fax +61 3 8412 7040

�